Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study

View Full Paper
Ask AI
Bookmark
Share

Authors

LPLia PalombaBHBrian T. HillMKManali Kamdar

Discussion

Loading...

Member takes

Overview

Phase 2 trial reports improvement in quality of life and functioning in patients receiving CAR T cell therapy after third-line treatment.

Key Points

  • To evaluate patient-reported outcomes after treatment with CAR T cell therapy liso-cel in R/R MZL patients.
  • Conducted a Phase 2, open-label, single-arm study called TRANSCEND FL.
  • Patients with third-line or later R/R MZL received liso-cel and completed quality of life assessments at multiple time points.
  • Key PRO scales included EORTC QLQ-C30, FACT-LymS, and EQ-5D-5L.
  • 60 evaluated patients reported initial deterioration in quality of life metrics, followed by improvements after 2 months.
  • Significant positive changes were noted in global health status, physical functioning, and fatigue.
  • Most patients experienced clinically meaningful improvements in PROs after treatment.

Cite This Study

Palomba et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c3https://doi.org/10.1182/blood-2025-709
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL2025 · 2 citations
  2. 2Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL): First results from CIBMTR.2026
  3. 3Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.2026
  4. 4Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.2024
  5. 5Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study2024 · 143 citations